BroadenBio Co.

BiotechnologySeries ABeijing, Chinabroadenbio.com

Latest round

Series A

Last raised

Dec 2025

Total raised

$14M

Investors

4

About BroadenBio Co.

, Ltd. operates as a biopharmaceutical company that focuses on immuno-oncology and autoimmune diseases fields. Mr. Xingmin Zhang is the founder and CEO of the company. The company works with clinical research institutions and healthcare stakeholders to develop novel small-molecule therapeutics. Its pipeline includes BB102, a FGFR4 inhibitor in Phase II clinical trials for hepatocellular carcinoma, BB3008 in Phase Ib clinical development with immunomodulatory properties, and multiple preclinical candidates addressing oncology and autoimmune disease indications. The company plans to advance its lead clinical programs, expand its preclinical pipeline and progress selected assets toward international clinical development and regulatory pathways.

Who invested in BroadenBio Co.

4 investors across 3 rounds

See all investors in BroadenBio Co.

Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.

Funding rounds

  1. Series A

    Dec 12, 2025

    Amount

    $14M

    Investors

    Locked

  2. Angel

    Mar 1, 2020

    Amount

    Undisclosed

    Investors

    Locked

  3. Angel

    Aug 23, 2018

    Amount

    Undisclosed

    Investors

    Locked

Questions about BroadenBio Co.

Who invested in BroadenBio Co.?

BroadenBio Co. has 4 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.

How much funding has BroadenBio Co. raised?

BroadenBio Co. has raised 3 venture rounds. Sign up free to see how much each round raised and the total.

When did BroadenBio Co. last raise money?

BroadenBio Co.'s most recent round on record is a Series A, in Dec 2025.

What does BroadenBio Co. do?

BroadenBio Co. is a biotechnology company.

Where is BroadenBio Co. headquartered?

BroadenBio Co. is headquartered in Beijing, China.

Which VCs invest in companies like BroadenBio Co.?

Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at BroadenBio Co.'s stage. Their profiles are linked below.

Raising like BroadenBio Co.? Find the right VCs.

Capital Atlas matches your startup to active investors by stage, sector and region.

Free to start. Upgrade when you're ready to reach out.